Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)

NCT00243230 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Vicriviroc 30 mg
DRUG: Vicriviroc 20 mg
DRUG: Placebo
DRUG: Placebo
DRUG: Background ART Regimen

Sponsor

Merck Sharp & Dohme LLC